Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Cancer Cell · 2025-04 · 43 (4) · 641-664
DOI: 10.1016/j.ccell.2025.03.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell, 2025-04. Verfasst von Stephen L Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA; Medical Scientist Training Program, Case Western Reserv…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 276 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have improved outcomes of patients with many different cancers. These antibodies target molecules such as programmed cell death 1 (PD-1) or cytotoxic T lymphocyte associated protein 4 (CTLA-4) which normally function to limit immune activity. Treatment with ICIs reactivates T cells to destroy tumor cells in a highly specific manner, which in some patients, results in dramatic remissions and durable disease control. Over the last decade, much effort has been directed at characterizing factors that drive efficacy and resistance to ICI therapy. Food and Drug Administration (FDA)-approved biomarkers for ICI therapy have facilitated more judicious treatment of cancer patients and transformed the field of precision oncology. Yet, adaptive immunity against cancers is complex, and newer data have revealed the potential utility of other biomarkers. In this review, we discuss the utility of currently approved biomarkers and highlight how emerging biomarkers can further improve the identification of patients who benefit from ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA; Medical Scientist Training Program, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Gen…
- Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA; National Center for Regenerative Medicine, Cleveland, OH, USA. Electronic address: chant2@ccf.org.
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- California Community Foundation
- National Institutes of Health
- NIH National Institute of General Medical Sciences
Zitieren
APA
Wang, S. L., & Chan, T. A. (2025). Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell, 43(4), 641-664. https://doi.org/10.1016/j.ccell.2025.03.006
Vancouver
Wang SL, Chan TA. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell. 2025;43(4):641-664. doi:10.1016/j.ccell.2025.03.006
BibTeX
@article{Wang2025,
author = {Wang, Stephen L and Chan, Timothy A},
title = {Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {4},
pages = {641--664},
doi = {10.1016/j.ccell.2025.03.006}
}
EUVIMED